Oral sucrosomial iron's effect on exercise and quality of life in heart failure patients
Official title: Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure: a Randomized, Placebo-controlled Trial (RISE-HF)
Run by Azienda Ospedaliero, Universitaria Pisana · NCT06270498 · Data updated 2026-11-12
This study is testing if a new type of oral iron can help people with heart failure and low iron feel better and exercise more easily compared to a placebo.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Azienda Ospedaliero, Universitaria Pisana Academic / other |
| Locations | 1 site (Pisa, Tuscany) |
| Status | Recruiting |
| Started | March 14, 2024 |
| Main results expected | March 14, 2026 |
| Study ends | June 14, 2026 |
| Registry record updated | October 1, 2025 |
| Trial ID | NCT06270498 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with chronic heart failure, left ventricular ejection fraction less than 50%, and documented iron deficiency.
✕Probably not a fit
Patients who require immediate iron repletion through intravenous methods or those with severe anemia may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates how oral sucrosomial iron affects exercise capacity and quality of life in patients suffering from chronic heart failure and iron deficiency. Participants will be divided into two groups, one receiving oral sucrosomial iron and the other a placebo. The primary outcomes will be measured through a six-minute walk test for exercise capacity and the Kansas City Cardiomyopathy Questionnaire for quality of life. The study aims to determine if this new oral iron formulation can improve symptoms compared to traditional treatments.
Why it matters
Potential benefit: If successful, this treatment could significantly enhance exercise capacity and quality of life for patients with heart failure and iron deficiency.
How similar studies have gone: Previous studies have shown that intravenous iron can improve symptoms in similar patient populations, but the use of oral sucrosomial iron is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Chronic HF (New York Heart Association \[NYHA\] functional class II-IV) patients, on optimal therapy, and clinically stable for at least 4 weeks with no dose changes of HF drugs 2. LVEF\<50% at screening visit (historical value can be used if performed within 6 months of screening visit) 3. Either a documented hospitalization for HF in the previous 12 months of enrolment or an elevated NT-proBNP: ≥250 pg/mL (or BNP ≥75 pg/mL) for patients in normal sinus rhythm; ≥1,000 pg/mL (or BNP ≥400 pg/mL) for patients in atrial fibrillation 4. TSAT \<20% 5. Hemoglobin 10.0-16.0 g/dL 6. Rapid iron repletion with intravenous iron is not considered a clinical necessity by physicians after reviewing patient medical record (if anaemia is present, its grade is no more than mild) 7. Age ≥18 years, male and female 8. Willingness to provide informed consent 9. Subjects who decide to use single or dual contraceptive methods to avoid conceiving during the study period Exclusion Criteria: 1. Neuromuscular, orthopedic or other non-cardiac condition that prevents the patient from exercise testing 2. Exercise training program in the previous 3 months, or planned in the next 3 months 3. Recent (\<3 month) acute coronary syndrome, coronary artery bypass surgery, percutaneous coronary interventions, transient ischemic attack, or stroke 4. Severe valvular disease, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, acute myocarditis 5. Atrial fibrillation or flutter with a ventricular response rate of \>100 beats per minute at rest 6. Temperature ≤38 °C (oral or equivalent) or active infection as defined by current use of oral or intravenous antimicrobial agents 7. Need for blood transfusion within the last month 8. Hb\<10 g/dL or Hb\>16 g/dL 9. Rapid iron repletion with intravenous iron is considered a clinical necessity by physicians after reviewing patient medical record 10. Documented active gastrointestinal bleeding 11. Oral iron, i.v. iron or erythropoietin stimulating agent within the last 3 months 12. eGFR ≤15 mL/min or on hemodialysis 13. Chronic liver disease and/or alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range 14. Active cancer 15. Evidence of iron overload (ferritin \>400 ng/mL) 16. Hypersensitivity to any of the study products or known severe allergies 17. Participation in another study 18. Low body weight (≤35 kg) 19. Known or anticipated pregnancy in the next 4 months 20. Need for forbidden medications 21. Breastfeeding 22. Consumption of iron-rich foods or any food that alter iron absorption (i.e. food rich in vitamin C) due to dietary requirements 23. Any pathological condition or disease associated with a reduction or an impairment of intestinal iron absorption (i.e., prior gastrectomy, atrophic gastritis, bariatric surgery, coeliac disease)
Where it's running
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Tuscany, Italy Recruiting
Study contacts
- Principal investigator: Gabriele Masini, MD PhD — University of Pisa
- Study coordinator: Gabriele Masini, MD PhD
- Email: gabriele.masini@unipi.it
- Phone: 0039 050996712
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Voice-based detection of heart failure deterioration using Noah Labs Vox
This study tests whether a voice-analysis app can flag worsening heart failure in adults by comparing its alerts to standard weight-based monitoring.
-
Iron status prediction in elderly with inflammation
This study tests a model to tell true iron deficiency from inflammation-related anemia in people aged 75 and older who are hospitalized with inflammation.
-
Mobile-based telemedicine to improve quality of life for chronic heart failure patients
We’re testing whether a mobile phone–based program that sends reminders, education, and follow-up can improve quality of life for adults with chronic heart failure in Ethiopia.
-
Lactoferrin with low-dose iron to boost iron levels and aerobic fitness in active women
We will test whether taking lactoferrin with a small daily dose of iron helps raise iron stores and improve aerobic performance in menstruating women with low ferritin.
-
Restoring gut bacteria in adults with chronic heart failure
This trial tests whether replacing gut bacteria with healthy donor bacteria (intestinal microbiota transplantation) can reduce inflammation and improve function in adults with chronic heart failure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.